8-K: ORIC Enozertinib Shows Best-in-Class Potential in NSCLC

ORIC Pharmaceuticals presented positive Phase 1b data for enozertinib (ORIC-114) in EGFR-mutated NSCLC, demonstrating strong systemic and CNS activity.

Summary

• Enozertinib (ORIC-114) Phase 1b trial data for EGFR-mutated Non-Small Cell Lung Cancer (NSCLC) was presented, highlighting its potential best-in-class profile.
• Systemic activity in 2L EGFR exon 20 showed a 45% Objective Response Rate (ORR), exceeding the 22% competitor benchmark.
• Systemic activity in previously treated (median 3L) EGFR PACC showed a 36% ORR, slightly below the 40% competitor benchmark.
• Preliminary 1L systemic activity demonstrated a 67% ORR in EGFR exon 20 and an 80% ORR in EGFR PACC.
• Convincing 1L CNS activity was observed with 100% intracranial ORR in both EGFR exon 20 and EGFR PACC, including in patients with active brain metastases.
• Enozertinib exhibited a competitive safety profile with no significant off-target toxicity and manageable on-target toxicity, resulting in a low rate of discontinuations.
• The 80 mg once-daily dose was selected as the recommended dose for potential Phase 3 development.
• Enrollment and follow-up continue in 1L EGFR exon 20 and 1L EGFR PACC, with the next update expected mid-2026.
• The estimated commercial opportunity for enozertinib in the US is ~$3.0 to $3.5 billion annually, addressing approximately 9,000 patients with NSCLC.
• ORIC's cash and investments of $413 million as of September 30, 2025, are expected to fund the company into the second half of 2028.

Sentiment

Score: 8

Explanation: The data presented for enozertinib shows strong efficacy, particularly in CNS activity and 1L settings, exceeding benchmarks in key areas. The safety profile is competitive, and the company has a solid financial runway. While one benchmark was slightly missed, the overall profile is highly positive and suggests significant commercial potential.

Positives

• Enozertinib's systemic activity in 2L EGFR exon 20 achieved a 45% ORR, significantly exceeding the competitor benchmark of 22% ORR.
• Preliminary 1L systemic activity is highly competitive, with 67% ORR in EGFR exon 20 and 80% ORR in EGFR PACC.
• Demonstrated convincing 1L CNS activity with 100% intracranial ORR in both EGFR exon 20 and EGFR PACC, including in patients with active brain metastases, addressing a critical unmet need.
• Competitive safety profile with predominantly Grade 1-2 adverse events, no significant off-target toxicities (e.g., cardiac, hematologic, liver), and a low rate of discontinuations.
• Achieved robust circulating tumor DNA (ctDNA) responses, with clearance rates of 69% (80 mg) and 67% (120 mg) in 2L EGFR exon 20, and 71% in 1L EGFR exon 20.
• Responses were generally achieved early, and most patients remain on treatment (67% of 2L EGFR exon 20 responders, 80% of 1L EGFR exon 20 responders, 75% of 3L EGFR PACC responders).
• Preclinical data shows enozertinib has superior potency across EGFR exon 20 and atypical mutations, exquisite selectivity, and high brain penetration compared to competitor agents.
• The 80 mg once-daily dose was selected for potential Phase 3 development due to a better tolerability profile compared to the 120 mg dose.
• Strong financial position with $413 million in cash and investments as of September 30, 2025, expected to fund operations into 2H 2028, beyond primary endpoint readouts from first Phase 3 trials for both enozertinib and ORIC-944.

Negatives

• Systemic activity in previously treated (median 3L) EGFR PACC (36% ORR) was slightly below the 40% competitor benchmark.
• The 120 mg dose cohort experienced a higher rate of dose reductions (57% in 2L EGFR exon 20, 80% in 1L EGFR exon 20, 68% in previously treated EGFR PACC) compared to the 80 mg dose, leading to the selection of 80 mg for Phase 3.
• One Grade 4 treatment-related adverse event (pneumonitis) was observed at the 120 mg dose in 2L EGFR exon 20 patients.

Risks

• The timing of the initiation, progress, and results of preclinical studies and clinical trials may vary.
• Risks are associated with the process of developing and commercializing drugs that are safe and effective for use in humans and operating as an early clinical stage company.
• Negative impacts of health emergencies, economic instability, or international conflicts could affect operations, including clinical trials.
• The potential for current or future clinical trials of product candidates to differ from preclinical, initial, interim, preliminary, or expected results exists.
• The ability to advance product candidates into, and successfully complete, clinical trials is not guaranteed.
• The timing or likelihood of regulatory filings and approvals may be uncertain.
• Changes in plans to develop and commercialize product candidates could occur.
• Estimates of the number of patients who suffer from the diseases targeted and the number of patients that may enroll in clinical trials may be inaccurate.
• The commercialization of product candidates, if approved, faces uncertainties.
• The ability to successfully manufacture and supply product candidates for clinical trials and for commercial use, if approved, is a risk.
• Potential benefits and costs of strategic arrangements, licensing, and/or collaborations may not materialize as expected.
• There is a risk of the occurrence of any event, change, or other circumstance that could give rise to the termination of license or collaboration agreements.
• Estimates regarding expenses, future revenue, capital requirements, and needs for financing, as well as the ability to obtain capital, are subject to uncertainty.
• The sufficiency of existing cash and investments to fund future operating expenses and capital expenditure requirements is an ongoing consideration.
• The ability to retain the continued service of key personnel and to identify, hire, and retain additional qualified professionals is crucial.
• The implementation of the business model and strategic plans for the business and product candidates carries inherent risks.
• The scope of protection able to be established and maintained for intellectual property rights, product candidates, and the pipeline is a risk factor.
• The ability to contract with third-party contract research organizations, suppliers, and manufacturers and their ability to perform adequately is a dependency.
• The pricing, coverage, and reimbursement of product candidates, if approved, are subject to market and regulatory factors.
• Developments relating to competitors and the industry, including competing product candidates and therapies, could impact the company.
• Regulatory developments in the United States and foreign countries may affect operations.
• General economic and market conditions can influence business performance.

Future Outlook

ORIC Pharmaceuticals expects to provide the next update on 1L EGFR exon 20 and 1L EGFR PACC data by mid-2026, ahead of potential initiation of Phase 3 trials for enozertinib and ORIC-944 in 2026. The company's existing cash and investments are projected to fund operations into the second half of 2028, covering primary endpoint readouts from its first Phase 3 trials.

Management Comments

• Enozertinib establishes potential best-in-class profile in EGFR-mutated NSCLC.
• Enozertinib has the potential to address ~9,000 patients with NSCLC annually, representing a commercial opportunity of ~$3.0 to $3.5 billion in the US alone.
• Enozertinib is a potential best-in-class inhibitor of EGFR exon 20 and PACC mutations, with superior potency and selectivity, and excellent brain-penetrance driving intracranial responses.
• Two potential best-in-class programs with initiation of registrational trials expected in 2026; Cash runway into 2H 2028, beyond Phase 3 data readouts from both programs.

Industry Context

The filing highlights a significant unmet need for CNS-active therapies in EGFR exon 20 mutant NSCLC and EGFR PACC mutant NSCLC, where current treatments often fail to address brain metastases effectively. Enozertinib's strong CNS activity positions it to potentially fill this gap, offering a differentiated profile in a market with a high burden of CNS disease. The estimated annual commercial opportunity of $3.0 to $3.5 billion in the US alone underscores the substantial market potential for an effective therapy in these patient populations.

Comparison to Industry Standards

• Enozertinib's 2L EGFR exon 20 ORR of 45% exceeds the benchmark ORR of 22% (Piotrowska et al. J Clin Oncol (2025) and Udagawa et al. WCLC (2025)).
• Enozertinib's 3L EGFR PACC ORR of 36% is slightly below the benchmark ORR of 40% (Piotrowska et al. J Clin Oncol (2025) and Udagawa et al. WCLC (2025)).
• Preclinical data shows enozertinib has superior potency across EGFR exon 20 and atypical mutations compared to zipalertinib, firmonertinib, and silevertinib.
• Enozertinib demonstrates an exquisitely clean kinome panel, inhibiting fewer off-target wildtype kinases (0) compared to zipalertinib (7), firmonertinib (4), and silevertinib (25).
• Enozertinib exhibits superior brain penetration and strong tumor regressions in an intracranial NSCLC model compared to mobocertinib and osimertinib.
• Current therapies like mobocertinib and amivantamab + chemotherapy show limited benefit for patients with baseline CNS metastases, with median Progression Free Survival of 3.7 months and 8.1 months respectively, and risk reductions of 37% and 67% for patients without CNS metastases. Enozertinib's 100% intracranial ORR in 1L patients with active brain metastases suggests a significant advantage over these existing options.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, potential for a best-in-class drug, large market opportunity, and extended cash runway.
• Patients with EGFR-mutated NSCLC: Potential for a new, highly effective treatment, especially for those with brain metastases, addressing a significant unmet medical need.
• Healthcare Providers: New therapeutic option for a challenging patient population.

Next Steps

• Continue enrollment and follow-up in 1L EGFR exon 20 and 1L EGFR PACC trials.
• Next data update for 1L EGFR exon 20 and 1L EGFR PACC expected mid-2026.
• Potential initiation of Phase 3 trial(s) for enozertinib in 2026.
• Combination dose exploration with AR inhibitor(s) for ORIC-944 in 1H 2025.
• Updated combination data with AR inhibitors(s) for ORIC-944 in 2H 2025.
• Combination dose optimization with AR inhibitor(s) for ORIC-944 in 1Q 2026.
• Mid-2026: 1L EGFR PACC and 1L EGFR exon 20 combination with SC amivantamab data.

Key Dates

Recommendation

The filing presents compelling Phase 1b data for enozertinib, demonstrating a potential best-in-class profile in EGFR-mutated NSCLC, particularly with its strong systemic and CNS activity, including 100% intracranial ORR in first-line settings. This addresses a critical unmet need for patients with brain metastases. The competitive safety profile and selection of an optimal dose for Phase 3 development de-risk future clinical progression. With a substantial estimated market opportunity of $3.0-$3.5 billion annually in the US and a cash runway extending into 2H 2028, well beyond anticipated Phase 3 data readouts, ORIC Pharmaceuticals is strongly positioned for significant value creation. The positive clinical outcomes and clear path to registrational trials make this a highly attractive investment.

Keywords

ORIC Pharmaceuticals, Enozertinib, ORIC-114, NSCLC, EGFR mutation, EGFR exon 20, EGFR PACC, Non-Small Cell Lung Cancer, Phase 1b, Clinical Trial, Oncology, Brain Metastases, Tyrosine Kinase Inhibitor, TKI, Biotechnology, Pharmaceuticals